Sign in

Devanjana Chatterjee

Research Analyst at Jones

Debanjana Chatterjee is an Analyst at JonesTrading, specializing in the US general equity market with a focus on companies such as Clearside Biomedical Inc (CLSD), Intellia Therapeutics (NTLA), and Optinose (OPT). She has demonstrated a remarkable performance track record, with a 100% success rate and an average return of 21.8% per rating over a one-year window, ranking #4,638 among Wall Street analysts according to TipRanks. Chatterjee began issuing ratings for JonesTrading in 2024 and has consistently provided profitable recommendations since then; her most notable trade was a 'Buy' on Clearside Biomedical yielding a 31% return. While her FINRA registration and securities licenses are not listed publicly, she is recognized for her strong analytical acumen and quantitative expertise within the sector.

Devanjana Chatterjee's questions to KalVista Pharmaceuticals (KALV) leadership

Devanjana Chatterjee's questions to KalVista Pharmaceuticals (KALV) leadership • Q1 2026

Question

Devanjana Chatterjee asked what payers would typically require in terms of safety or efficacy failure on Acadevant to approve ECTERLEET, particularly in cases where a generic step-through might be required. She also inquired if the company would share KPIs related to the percentage of patients covered in the future.

Answer

Nicole Sweeny, Chief Commercial Officer, explained that for the minority of patients (20%) without prior generic Acadevant experience, physicians find it simple to describe failure, citing reasons like injection site reactions or difficulties with sub-Q administration for abdominal attacks or hand swelling. She stated that future sharing of specific payer-related KPIs is yet to be determined, but the company recognizes the interest in providing more clarity on ongoing paid access and policy establishment.

Ask Fintool Equity Research AI

Devanjana Chatterjee's questions to KalVista Pharmaceuticals (KALV) leadership • Q1 2026

Question

Devanjana Chatterjee asked what specific safety or efficacy failures on Acadevant payers would require to approve EKTERLY, especially concerning generic step-throughs. She also inquired if the company would share a 'percent covered' KPI at some point.

Answer

Nicole Sweeny, Chief Commercial Officer, explained that most patients have prior experience with generic Acadevant, facilitating step-throughs. For others, physicians can cite reasons like injection site reactions, difficulty with sub-Q administration for abdominal attacks, or hand swelling. She indicated that while specific 'percent covered' KPI details are to be determined, the company recognizes the interest in providing more clarity on payer efforts and ongoing paid access.

Ask Fintool Equity Research AI